US Inhaled Insulin Dose Titration Study

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

March 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Exubera (inhaled insulin)

PROCEDURE

8-point glucose diary (to assess pre- and post prandial glucoses)

PROCEDURE

Meal Tolerance Test

PROCEDURE

24-hour continuous glucose monitoring (at select sites)

PROCEDURE

Pulmonary Function Testing

PROCEDURE

Hypoglycemic Event Monitoring

PROCEDURE

Laboratory Assessments

BEHAVIORAL

Nutritional Counseling and Diabetes Education

Trial Locations (16)

Unknown

Pfizer Investigational Site, Birmingham

Pfizer Investigational Site, Los Angeles

Pfizer Investigational Site, New Britain

Pfizer Investigational Site, Norwalk

Pfizer Investigational Site, Hollywood

Pfizer Investigational Site, Atlanta

Pfizer Investigational Site, Boise

Pfizer Investigational Site, Hayden

Pfizer Investigational Site, Baton Rouge

Pfizer Investigational Site, Boston

Pfizer Investigational Site, Albany

Pfizer Investigational Site, Syracuse

Pfizer Investigational Site, Dallas

Pfizer Investigational Site, El Paso

Pfizer Investigational Site, San Antonio

Pfizer Investigational Site, Bennington

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Pfizer

INDUSTRY

NCT00246623 - US Inhaled Insulin Dose Titration Study | Biotech Hunter | Biotech Hunter